Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Intec Pharma Ltd (NASDAQ:INDP) stock has reached a new 52-week low, trading at $0.7, as the company faces ongoing market headwinds. With a market capitalization of just $9.9 million and a current ratio of 3.42, the company maintains strong liquidity despite challenges. According to InvestingPro analysis, the stock appears slightly undervalued at current levels. This latest price level reflects a significant downturn from the previous year, with the stock experiencing a substantial 1-year change of -57.7%. The company’s next earnings report is due on March 13, with analysts setting price targets ranging from $5 to $12. Investors are closely monitoring INDP’s performance as it navigates through a challenging period, with the hope for potential recovery or strategic changes that may influence the stock’s trajectory in the upcoming quarters. InvestingPro subscribers can access 7 additional key insights about INDP’s financial health and future prospects.
In other recent news, Indaptus Therapeutics has received authorization from Health Canada to expand its U.S. clinical trial for Decoy20 to Canadian sites. This expansion aims to accelerate patient enrollment and enhance the research program for the treatment of solid tumors. The INDP-D101 trial will now include Canadian patients under the existing protocol, which involves weekly dosing of Decoy20. Indaptus also plans to propose an amendment to include a combination trial of Decoy20 with tislelizumab, a PD-1 checkpoint inhibitor developed by Beigene (NASDAQ:ONC). Health Canada’s approval followed a thorough review of the safety data and trial design. Chief Medical (TASE:BLWV) Officer Roger Waltzman expects the addition of Canadian sites to expedite the collection of clinical data from a broader population. This development is seen as crucial for assessing Decoy20’s potential to activate immune responses, which could be key in treating solid tumors. Indaptus aims to refine Decoy20’s dosing regimen and improve patient outcomes through enhanced trial infrastructure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.